Answers are grounded in this paper and cite their sources.
BACKGROUND & AIMS: Hepatocellular carcinoma (HCC) is an aggressive disease for which effective therapeutic options remain limited. Progress in therapeutic development has been hampered by the lack of preclinical models that recapitulate human HCC and support the evaluation of multimodal therapies. Here, we employed CRISPR editing to identify alterations that drive hepatocyte transformation and establish genetically defined HCC models. METHODS: Hepatocytes were isolated from pigs (n = 7) and subjected to combinations of 2-4 gene alterations, including CRISPR-mediated knockout of tumor suppressor genes (TP53, PTEN, CDKN2A, AXIN1), with or without c-Myc overexpression. Resulting cells were injected subcutaneously into immunodeficient mice to assess their tumorigenicity and histological features. To establish a large-animal model, autologous transformed hepatocytes were implanted at four intrahepatic sites in pigs (n = 5). Transcriptomic profiling of cells, xenografts, and porcine tumors was conducted by RNA sequencing, using FDR <0.05 for differential gene expression analysis. RESULTS: ; sgPTEN and/or sgCDKN2A recapitulated histological features of human liver cancer, including clear cell, trabecular, and pseudoglandular HCC and cholangiocarcinoma. Transcriptomic analysis of transformed cells and xenograft tumors revealed activation of cell-cycle pathways and similarities to human HCC profiles. Autologous implantation of transformed hepatocytes generated intrahepatic tumors at 7/8 injection sites (87.5%) in two pigs, providing proof of concept for an immunocompetent HCC model in wild-type pigs. CONCLUSIONS: This study delineates cooperative oncogenic alterations that drive hepatocyte transformation ex vivo and provides cell and animal models that recapitulate key histological and molecular features of human HCC. IMPACT AND IMPLICATIONS: Hepatocellular carcinoma (HCC) shows limited responses to available treatments, underscoring the urgent need for translational preclinical models. Through ex vivo CRISPR editing of clinically relevant genes in porcine hepatocytes, we established cell and animal models that recapitulate key molecular and histological features of human HCC. This platform provides a foundation for future mechanistic studies, genotype-phenotype mapping, and preclinical testing of precision therapies. Moreover, the porcine model's size and physiological similarity to humans make it a promising model for evaluating locoregional therapies and device-based therapies in an immunocompetent setting.
No takes yet. Share an insight, caveat, or question.
Elkhadragy et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: